1
Return

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma

delete2026-07-29
delete0
PRE
AI
L
Lilit Karapetyan *
J
Jin Xu
K
Kimberly Ward
D
Denise Kalos
B
Benjamin Schachner
J
Johannes Ali
X
Xiaofei Song
J
Joel Kuriakose
M
MacLean S. Hall
J
Jamie Chau
C
Cheryl A. Cox
A
Ayah N. Al-Bzour
R
Rana Falahat
M
Matthew C. Perez
J
John E. Mullinax
J
Jonathan S. Zager
R
Ricardo González
V
Vernon K. Sondak
K
Kenneth Y Tsai
J
Jane L. Messina
DOI：10.1016/j.medj.2026.101231delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• Prior ICI reduces stem-like CD8+ TILs, co-stimulatory signaling, and TCR diversity • LAG-3+CD8+ TILs mark tumor-reactive cells and predict response and PFS • Tumor TLS correlates with survival benefit and CD8+-dominant TIL expansion • Spatial transcriptomics identifies immune signatures associated with response

Journal

Med cover
Med
IF:
11.8
Papers:
771
Citations:
2.2K

Organization

No organization information available
Cited Papers

Cited Papers

Citing Papers

Citing Papers